Jobaaj Stories
On May 8, 2025, Niva Bupa Health Insurance Company Ltd's stock zoomed more than 14% on the NSE, touching an intraday high of ₹92.45 per share, a four-month high. The company's stunning Q4 FY25 numbers triggered the surge. The details follow:
Niva Bupa's Q4 FY25 net profit increased 31.2% year over year to ₹206.08 crore from ₹157.06 crore in the same quarter of the previous fiscal year, according to an exchange filing made on May 7. Net written premiums increased 20.99% to ₹16.7211 billion during the quarter, while gross written premiums increased 18.14% to ₹20.7865 billion.
The success of Niva Bupa's business strategy and operational management is what led to its strong Q4 performance. The business is demonstrating its competitiveness in the health insurance market by steadily growing its market share in the retail health sector. Its profitability is also aided by its effective claim processing and robust underwriting capabilities
Krishnan Ramachandran, MD and CEO of Niva Bupa, highlighted the company's strategic stance in India's developing health insurance market and its dedication to growth and innovation, attributing its strong success to consumer trust.
With a "Buy" rating and a target price of ₹100, Motilal Oswal began covering the firm in its most recent analysis, citing promising growth possibilities.
With a target price of ₹90 and a "Buy" rating, ICICI Securities also started covering. Niva Bupa is well-positioned to profit from India's underserved health insurance industry, according to the broking.
Disclaimer: The information provided in this article is for informational purposes only and does not constitute financial advice. Investors are advised to do their own research or consult with a professional advisor before making any investment decisions. Jobaaj Media does not assume any responsibility for losses arising from investment decisions influenced by this news.
